Regulatory 2026-02-05 | Full Year and Q4 Report 2025: FDA Accepts Orviglance NDA for Review PDF Report Presentation Webcast
Regulatory 2026-01-21 | Ascelia Pharma Announces Deputy CEO Julie Waras Brogren to Leave the Company PDF Report Presentation Webcast
Regulatory 2025-12-22 | Nomination Committee Appointed for AGM 2026 in Ascelia Pharma AB PDF Report Presentation Webcast
Regulatory 2025-11-28 | Change in Number of Shares and Votes in Ascelia Pharma AB PDF Report Presentation Webcast
Regulatory 2025-11-19 | Ascelia Pharma Resolves on Conversion of Series C Shares into Ordinary Shares for Delivery to Participants in Incentive Program PDF Report Presentation Webcast
Regulatory 2025-11-05 | Quarterly Report Q3 2025: Orviglance NDA Submitted to the FDA PDF Report Presentation Webcast
Regulatory 2025-11-03 | Ascelia Pharma Announces Management Changes to Support Future Growth PDF Report Presentation Webcast
Regulatory 2025-09-30 | Change in Number of Shares and Votes in Ascelia Pharma AB PDF Report Presentation Webcast
Regulatory 2025-09-22 | Ascelia Pharma Has Completed a Directed Share Issue of Approximately SEK 30 Million PDF Report Presentation Webcast
Regulatory 2025-09-22 | Ascelia Pharma Intends to Carry Out a Directed Share Issue of Approximately SEK 30 Million PDF Report Presentation Webcast
Regulatory 2025-09-02 | Fenja Capital II A/S Requests Conversion of All Outstanding Convertibles for a Total Nominal Amount of SEK 7.5 Million PDF Report Presentation Webcast
Regulatory 2025-08-21 | Half-Year Report 2025: Orviglance NDA Submission Approaching PDF Report Presentation Webcast
Regulatory 2025-05-16 | Quarterly Report Q1 2025: Positive Outcome of Orviglance FDA Meeting in Advance of the NDA Submission PDF Report Presentation Webcast
Regulatory 2025-05-07 | Bulletin from the Annual General Meeting in Ascelia Pharma AB on 7 May 2025 PDF Report Presentation Webcast
Regulatory 2025-04-30 | Change in Number of Shares and Votes in Ascelia Pharma AB PDF Report Presentation Webcast
Regulatory 2025-04-16 | Ascelia Pharma Receives Gross Proceeds of SEK 43 Million from Exercise of Warrants Series TO 1 PDF Report Presentation Webcast
Regulatory 2025-04-11 | Annual Report 2024: Orviglance Advances to Registration Phase after Successful Phase 3 Study Completion PDF ESEF Report Presentation Webcast
Regulatory 2025-04-04 | Notice of Annual General Meeting in Ascelia Pharma AB PDF Report Presentation Webcast
